T Cell Repertoire Complexity Is Conserved after LLME Treatment of Donor Lymphocyte Infusions

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 12, 2007, Pages 1439-1447

  Friedman, Thea M ^a   Filicko O'Hara, Joanne ^b   Mookerjee, Bijoyesh ^b   Wagner, John L ^b   Grosso, Delores A ^b   Flomenberg, Neal ^b   Korngold, Robert ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Blood and marrow transplantation; Donor lymphocyte infusion; Spectratype; V repertoire analysis

Indexed keywords

COTRIMOXAZOLE; CYTARABINE; FLUDARABINE; LEUCYLLEUCINE METHYL ESTER; MELPHALAN; STEROID; T LYMPHOCYTE RECEPTOR BETA CHAIN; THYMOCYTE ANTIBODY; VALACICLOVIR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DONOR; DONOR LYMPHOCYTE INFUSION; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA RELAPSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MALE; TREATMENT RESPONSE;

ADULT; DIPEPTIDES; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION CHIMERA;

EID: 36048997581     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.09.008     Document Type: Article

References (39)

1. Ho V.T., and Soiffer R.J. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 98 (2001) 3192-3204
2. Roux E., Dumont-Girard F., Starobinski M., et al. Recovery of immune reactivity after T-cell-depleted bone marrow transplantation depends on thymic activity. Blood 96 (2000) 2299-2303
3. Johnson B.D., Drobyski W.R., and Truitt R.L. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant 11 (1993) 329-336
4. Kolb H.J., Gunther W., Schumm M., et al. Adoptive immunotherapy in canine chimeras. Transplantation 63 (1997) 430-436
5. Verfuerth S., Peggs K., Vyas P., et al. Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T-cell-depleted allogeneic bone marrow transplant and the effect of donor lymphocyte infusions on T-cell repertoire. Blood 95 (2000) 3990-3995
6. Guglielmi C., Arcese W., Dazzi F., et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood 100 (2002) 3877-3886
7. Or R., Hadar E., Bitan M., et al. Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation. Biol Blood Marrow Transplant 12 (2006) 1295-1301
8. Hsieh M.H., Varadi G., Flomenberg N., et al. Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk. Biol Blood Marrow Transplant 8 (2002) 303-315
9. + T cells each can utilize a perforin-dependent pathway to mediate lethal graft-versus-host disease in major histocompatibility complex-disparate recipients. Transplantation 64 (1997) 571-576
10. Clement M.V., Soulie A., Legros-Maida S., et al. Perforin and granzyme B: predictive markers for acute GVHD or cardiac rejection after bone marrow or heart transplantion. Nouv Rev Fr Hematol 33 (1991) 465-470
11. Takata M. Immunohistochemical identification of perforin-positive cytotoxic lymphocytes in graft-versus-host disease. Am J Clinical Pathol 103 (1995) 324-329
12. Graubert T.A., DiPersio J.F., Russell J.H., et al. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest 100 (1997) 904-911
13. Tsukada N., Kobata T., Aizawa Y., et al. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood 93 (1999) 2738-2747
14. Perez-Diez A., Joncker N.T., Choi K., et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109 (2007) 5346-5354
15. Thiele D.L., and Lipsky P.E. Apoptosis is induced in cells with cytolytic potential by L-leucyl-L-leucine methyl ester. J Immunol 148 (1992) 3950-3957
16. Thiele D.L., Charley M.R., Calomeni J.A., et al. Lethal graft-vs-host disease across major histocompatibility barriers: requirement for leucyl-leucine methyl ester sensitive cytotoxic T cells. J Immunol 138 (1987) 51-57
17. Blazar B.R., Thiele D.L., and Vallera D.A. Pretreatment of murine donor grafts with L-leucyl-L-leucine methyl ester: elimination of graft-versus-host disease without detrimental effects on engraftment. Blood 75 (1990) 798-805
18. Raff R.F., Severns E.M., Storb R., et al. Studies of the use of L-leucyl-L-leucine methyl ester in canine allogeneic marrow transplantation. Transplantation 55 (1993) 1244-1249
19. Rosenfeld C.S., Thiele D.L., Shadduck R.K., et al. Ex vivo purging of allogeneic marrow with L-Leucyl-L-leucine methyl ester: a phase I study. Transplantation 60 (1995) 678-683
20. + T cells differently expressing three cytolytic effector molecules. J Immunol 177 (2006) 4330-4340
21. + T lymphocytes. J Immunol 178 (2007) 4112-4119
22. +-selected allogeneic hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 11 (2005) 609-618
23. Friedman T.M., Varadi G., Hopely D.D., et al. Nonmyeloablative conditioning allows for more rapid T-cell repertoire reconstitution following allogeneic matched unrelated bone marrow transplantation compared to myeloablative approaches. Biol Blood Marrow Transplant 7 (2001) 656-664
24. Van Deerlin V.M., and Leonard D.G. Bone marrow engraftment analysis after allogeneic bone marrow transplantation. Clin Lab Med 20 (2000) 197-225
25. Lum L.G. The kinetics of immune reconstitution after human marrow transplantation. Blood 69 (1987) 369-380
26. Atkinson K. Reconstruction of the haemopoietic and immune systems after marrow transplantation. Bone Marrow Transplant 5 (1990) 209-226
27. Hakim F.T., Memon S.A., Cepeda R., et al. Age-dependent incidence, time course, and consequences of thymic renewal in adults. J Clin Invest 115 (2005) 930-939
28. + T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 332 (1995) 143-149
29. Porter D.L., and June C.H. T-cell reconstitution and expansion after hematopoietic stem cell transplantation: 'T' it up!. Bone Marrow Transplant 35 (2005) 935-942
30. Hsieh M.H., Patterson A.E., and Korngold R. T-cell subsets mediate graft-versus-myeloid leukemia responses via different cytotoxic mechanisms. Biol Blood Marrow Transplant 6 (2000) 231-240
31. + T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant 8 (2002) 625-632
32. + cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplant 34 (2004) 123-128
33. Thiele DL, Lipsky PE. The immunosuppressive activity of L-leucyl-L-leucine methyl ester: selective ablation of cytotoxic lymphocytes and monocytes. J Immunol. ;136:1038-1048.
34. Lee S.H., Bar-Haim E., Machlenkin A., et al. In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL. Cancer Gene Ther 1 (2004) 237-248
35. Dicker F., Kater A.P., Fukuda T., et al. Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells. Blood 105 (2005) 3193-3198
36. Seki N., Brooks A.D., Carter C.R., et al. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J Immunol 168 (2002) 3484-3492
37. Caldwell S.A., Ryan M.H., McDuffie E., et al. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases. J Immunol 171 (2003) 2402-2412
38. Schmaltz C., Alpdogan O., Kappel B.J., et al. T cells require TRAIL for optimal graft-versus-tumor activity. Nat Med 8 (2002) 1433-1437
39. Gale RP, Horowitz MM, Ash RC, et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med. 199;120:646-652.